Finance

Beta
Lists
RXST:NASDAQ
Rxsight Inc
$5.36
+4.48%
(+0.23) 1D
$5.37
+0.19% (+0.0100)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RXST...
Open
$5.13
High
$5.49
Low
$4.94
Mkt. cap
221.89M
Avg. vol.
871.49K
Volume
3.47M
52-wk high
$13.65
52-wk low
$4.48
EPS
-$1.14
Beta
1.14
Shares outstanding
41.40M
No. of employees
461
Open
$5.13
High
$5.49
Low
$4.94
Mkt. cap
221.89M
Avg. vol.
871.49K
Volume
3.47M
52-wk high
$13.65
52-wk low
$4.48
EPS
-$1.14
Beta
1.14
Shares outstanding
41.40M
No. of employees
461
News stories
From sources across the web
About Rxsight Inc
CEO-
Employees461
Founded1997
HeadquartersAliso Viejo, California, United States
SectorMedical device
Websiterxsight.com
Analyst ratings
Based on 6 analysts giving stock ratings to RXST in the past 3 months
Hold
Buy
1
Hold
4
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for RXST in the last 3 months.
Highest
Current $5.36
$11.00 (+105.22%)
Average
$9.67 (+80.41%)
Lowest
$8.00 (+49.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Travis Steed
Bank of America Securities
Sell
Maintained
-
-
05/14/2026
Steven Lichtman
William Blair
Hold
Maintained
-
-
05/08/2026
Thomas Stephan
Stifel Nicolaus
Hold
Maintained
$8.00
+49.3%
05/08/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
05/07/2026
David Saxon
Needham
Buy
Reiterated
$11.00
+105.2%
05/07/2026
Adam Maeder
Piper Sandler
Hold
Maintained
$10.00
+86.6%
05/07/2026
Patrick Wood
Morgan Stanley
Hold
Maintained
$10.00
+86.6%
03/06/2026
Danielle Antalffy
UBS
Hold
Maintained
$9.00
+67.9%
02/26/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
$11.00
+105.2%
02/26/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
33.64M
30.34M
32.61M
30.89M
Cost of goods sold
8.45M
6.11M
7.34M
7.40M
Cost of revenue
8.45M
6.11M
7.34M
7.40M
Research and development expenses
10.22M
9.06M
8.90M
9.47M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.98M
27.34M
27.70M
31.86M
Operating expense
39.19M
36.40M
36.60M
41.33M
Total operating expenses
47.64M
42.52M
43.94M
48.72M
Operating income
-14.00M
-12.18M
-11.34M
-17.83M
Other non operating income
-
-
-
-
EBT including unusual items
-11.75M
-9.81M
-9.15M
-15.88M
EBT excluding unusual items
-11.75M
-9.81M
-9.15M
-15.88M
Income tax expense
32.00K
10.00K
5.00K
6.00K
Effective tax rate
-0.27%
-0.10%
-0.05%
-0.04%
Other operating expenses
-
-
-
-
Net income
-11.79M
-9.82M
-9.15M
-15.88M
Net profit margin
-35.04%
-32.35%
-28.07%
-51.42%
Earnings per share
-0.08
-0.04
-0.03
-0.19
Interest and investment income
2.25M
2.38M
2.20M
1.95M
Interest expense
-5.00K
-4.00K
-5.00K
-3.00K
Net interest expenses
2.25M
2.37M
2.19M
1.95M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.22M
-11.32M
-10.49M
-17.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of RXST
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer